First 9 Months of 2019
First Quarter 2018 Key Highlights
? Completion of 2017 Audited Financial Statements (2nd year with unqualified audit opinion)
? $1.9 million of revenue in March 2018, largest single month in company’s history
? 5-star pharmacy rating
? Over $5.1 million in revenue during first quarter 2018, largest single quarter in company’s history
? Over 66,000 prescriptions filled during first quarter 2018, a 24% increase over the same period in 2017
? Increased number of prescriptions from Empower “U” 340B contract
? Completed expansion plans into Palm Beach County, Florida through acquisition of Touchpoint RX pharmacy
? Raised over $1.4 million for 340B charitable organizations
? Development and deployment of our online prescription management solution
? Acceptance of cryptocurrencies as a payment source
? Licensed in the following states: Colorado, Connecticut, Florida, Georgia, Illinois, Nevada, New Jersey, New York,
Pennsylvania, Texas, Utah, Arizona, Massachusetts
Second Quarter 2018 Key Highlights
? 5-star pharmacy rating
? Over $5.1 million in revenue during second quarter 2018, $10.3 million in revenue for the 6 months ended June 30th
? Over 67,000 prescriptions filled during second quarter 2018, 133,000 for the 6 months ended June 30th, a 23%
increase over the same period in 2017
? Completed acquisition of Touchpoint RX pharmacy to facilitate expansion plans in Palm Beach and Martin Counties
? Raised over $1.4 million for 340B charitable organizations during second quarter 2018, $2.7 million for the 6 months
ended June 30th
? Implemented TCGRx Pouch Packaging System at PharmCo in North Miami Beach
? Engaged CMW Media to build and expand marketing and communications channels and activities
? Development and deployment of our online prescription management solution
? Launched campaign to combat opioid abuse
? Licensed in the following states: Colorado, Connecticut, Florida, Georgia, Illinois, Nevada, New Jersey, New York,
Pennsylvania, Texas, Utah, Arizona, Massachusetts, Minnesota
Third Quarter 2018 Key Highlights
? 5-star pharmacy rating, including exceeding all Humana performance metrics that will lead to the refund of all DIR
fees collected by Humana.
? Over $5.4 million in revenue during third quarter 2018, $15.7 million in revenue for the 9 months ended September
30th.
? Over 26,000 prescriptions filled by the legacy business (i.e., excluding PharmCo 1002) during August 2018, the
highest single month for prescriptions filled in the Company’s history.
? Over 203,000 prescriptions filled by the legacy business (i.e., excluding PharmCo 1002) during the nine months
ended September 30, 2018, a 25% increase over the same period in 2017.
? Payoff of Chicago Venture Partners convertible promissory note during third quarter 2018.
? Completion and consolidation of Touchpoint RX, now doing business as PharmCo 1002, LLC, during third quarter
2018, including name and “doing business as” (DBA) changes – addition to the legacy business of $315,000 revenue
and approximately 9,000 prescriptions filled during the third quarter 2018.
? Addition of two new 340B contracts in July 2018, under which the Company began servicing in October 2018.
? Raised nearly $1.4 million for 340B charitable organizations during third quarter 2018, $4.1 million for the 9 months
ended September 30th.
? Licensed in the following states: Colorado, Connecticut, Florida, Georgia, Illinois, Nevada, New Jersey, New York,
Pennsylvania, Texas, Utah, Arizona, Massachusetts, Minnesota.
? Published articles on tele-pharmacy and other current developments in various trade periodicals during third
quarter 2018.
Market Data 
Markets 
AI
